# Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

> **NCT00924703** · PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 68 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **DRUG:** rAvPAL-PEG

## Key facts

- **NCT ID:** NCT00924703
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-13
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924703, "Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00924703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*